Date: 2015-01-11
Type of information: Collaboration agreement
Compound:
Company: illumina (USA - CA) University of Edinburgh (UK) University of Edinburgh Glasgow (UK)
Therapeutic area: Technology - Services - Cancer - Oncology - CNS diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 11, 2015, Illumina and the Universities of Edinburgh and Glasgow have announced a major investment in gene sequencing technology will secure Scotland\'s place as a world leader in a genomics revolution that is set to transform healthcare. The Universities of Edinburgh and Glasgow are to partner with Illumina in the £15 million project. The investment will establish The Scottish Genomes Partnership , which will install 15 state-of-the-art HiSeq X sequencing instruments divided between two hubs within the Universities. The Partnership will initially focus on very rapid screening of cancer patients, diagnosing childhood illnesses, disorders of the central nervous system and population studies. The Universities will draw on the Medical Genomics leadership based at the University of Glasgow\'s Wolfson Wohl Cancer Centre , a leading-edge translational research facility dedicated to cancer, and the expertise of Edinburgh Genomics, the UK\'s largest university-based gene sequencing facility.
Financial terms:
Latest news:
